Charlie Chung

Charlie Chung

Auto-generated profile, based on publicly available information

Charlie Chung

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PLPin-Ji Lei
Pin-Ji Lei
EPEthel R. Pereira
Ethel R. Pereira
PAPatrik Andersson
Patrik Andersson
ZAZohreh Amoozgar
Zohreh Amoozgar
JWJan Willem Van Wijnbergen
Jan Willem Van Wijnbergen
TPTimothy P. Padera
Timothy P. Padera
Tumor-draining lymph nodes (TDLNs) are important for tumor antigen–specific T cell generation and effective anticancer immune responses. However, TDLNs are often the primary site of metastasis, causing immune suppression and worse outcomes. Through cross-species single-cell RNA-Seq analysis, we identified features defining cancer cell heterogeneity, plasticity, and immune evasion during breast cancer progression and lymph node metastasis (LNM). A subset of cancer cells in the lymph nodes exhibited elevated MHC class II (MHC-II) gene expression in both mice and humans. MHC-II+ cancer cells lacked costimulatory molecule expression, leading to regulatory T cell (Treg) expansion and fewer CD4+ effector T cells in TDLNs. Genetic knockout of MHC-II reduced LNM and Treg expansion, while overexpression of the MHC-II transactivator, Ciita, worsened LNM and caused excessive Treg expansion. These findings demonstrate that cancer cell MHC-II expression promotes metastasis and immune evasion in TDLNs.

1 March 2026 in Cancer Research Communications
Verified
Journal Article
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
High-grade endometrial cancers (HGEC) disproportionately affect women of African ancestry and often resist currently available immunotherapies. Defining the mechanisms driving this resistance is impeded by a lack of preclinical models that preserve ancestral diversity and patient-matched tumor–immune interactions without confounding alloreactivity. To address this gap, we established a biobank of 85 endometrial cancer patient-derived organoids (PDO) from a diverse cohort, enriched for HGEC PDOs from African American patients, and paired these with autologous immune cells to develop a patient-specific PDO–immune cell coculture platform with real-time live-imaging readouts. Using this system, we found that HGECs evade immune surveillance through pronounced suppression of major histocompatibility complex (MHC) class I and II antigen presentation pathways relative to their matched normal counterparts. Restoring antigen presentation, either by IFNγ stimulation or epigenetic reprogramming via enhancer of zeste homolog 2 inhibition, rescued MHC expression and sensitized HGEC PDOs to autologous T cell–mediated cytotoxicity. Extending the platform to NK cells revealed heightened killing of low–MHC-I PDOs. Consistent with clinical observations, mismatch repair (MMR)-deficient HGEC PDOs exhibited stronger immune engagement than their MMR-proficient counterparts. Finally, this platform enabled evaluation of the safety and efficacy of emerging immunotherapies, including protease-activatable bispecific T-cell engagers and EGFR-targeted chimeric antigen receptor T cells. Together, this sustainable, scalable, ancestrally diverse autologous PDO–immune cell coculture platform offers a robust resource for dissecting immune evasion mechanisms and accelerating the development of new immunotherapies to address disparities in endometrial cancer outcomes. Significance: The efficacy of immunotherapy for HGECs remains limited, partly because current preclinical models poorly capture tumor heterogeneity and patient-specific immune microenvironment. These cancers disproportionately affect women of African ancestry, yet most studies rely on European ancestry samples. We developed an autologous PDO and immune cell coculture platform from patients of diverse ancestries. This system enables patient-level analysis of tumor–immune interactions to support development and testing of novel immunotherapeutic strategies.

25 March 2026
Verified
Other
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
High-grade endometrial cancers (HGEC) disproportionately affect women of African ancestry and often resist currently available immunotherapies. Defining the mechanisms driving this resistance is impeded by a lack of preclinical models that preserve ancestral diversity and patient-matched tumor–immune interactions without confounding alloreactivity. To address this gap, we established a biobank of 85 endometrial cancer patient-derived organoids (PDO) from a diverse cohort, enriched for HGEC PDOs from African American patients, and paired these with autologous immune cells to develop a patient-specific PDO–immune cell coculture platform with real-time live-imaging readouts. Using this system, we found that HGECs evade immune surveillance through pronounced suppression of major histocompatibility complex (MHC) class I and II antigen presentation pathways relative to their matched normal counterparts. Restoring antigen presentation, either by IFNγ stimulation or epigenetic reprogramming via enhancer of zeste homolog 2 inhibition, rescued MHC expression and sensitized HGEC PDOs to autologous T cell–mediated cytotoxicity. Extending the platform to NK cells revealed heightened killing of low–MHC-I PDOs. Consistent with clinical observations, mismatch repair (MMR)-deficient HGEC PDOs exhibited stronger immune engagement than their MMR-proficient counterparts. Finally, this platform enabled evaluation of the safety and efficacy of emerging immunotherapies, including protease-activatable bispecific T-cell engagers and EGFR-targeted chimeric antigen receptor T cells. Together, this sustainable, scalable, ancestrally diverse autologous PDO–immune cell coculture platform offers a robust resource for dissecting immune evasion mechanisms and accelerating the development of new immunotherapies to address disparities in endometrial cancer outcomes.Significance:The efficacy of immunotherapy for HGECs remains limited, partly because current preclinical models poorly capture tumor heterogeneity and patient-specific immune microenvironment. These cancers disproportionately affect women of African ancestry, yet most studies rely on European ancestry samples. We developed an autologous PDO and immune cell coculture platform from patients of diverse ancestries. This system enables patient-level analysis of tumor–immune interactions to support development and testing of novel immunotherapeutic strategies.


25 March 2026
Verified
Other
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
Bispecific TCE constructs facilitate cancer–immune cell interactions. A, Quantification of EpCAM protein expression levels of the MMRd and MMRp PDO lines measured by flow cytometry. MFI, mean fluorescent intensity. B, Representative images of autologous coculture using the MMRd HGEC PDO line. Red and green fluorescence represent organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase 3 signals. Scale bar, 70 μm. C, Representative images of autologous cancer–immune cell coculture using the MMRp HGEC PDO line. Scale bar, 70 μm. D, Colocalization of the MMRd HGEC PDOs and immune cells at 7 hours of coculture period. E, Viability of the MMRd PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 hours coculture period. F, Colocalization of the MMRp HGEC PDOs and immune cells at 42 hours of coculture period. G, Viability of the MMRd organoid in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 46 hours coculture period. Cas3, caspase-3. t test (A) and ordinary one-way ANOVA (D–G) were used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).

25 March 2026
Verified
Other
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
Organoid–NK cell coculture and autologous MMRp and MMRd organoid coculture validate our platform. A, Representative images of allogeneic NK cell coculture using a HGEC PDO line with or without IFNγ prestimulation. Red and green fluorescence represent HGEC PDOs and corresponding immune cells, respectively. Blue fluorescence represents active caspase 3 signals. Scale bar, 70 μm. B, Colocalization of PDOs and immune cells over the time of imaging. The area under the curve was used for statistical significance (ordinary t test). C, The end point viability of PDOs in the coculture measured by colocalization coefficient between organoid and caspase-3 signals. D, Representative images of coculture using MMRd and MMRp HGEC PDOs and autologous PBMCs. Scale bar, 70 μm. E, Quantification of MHC-I, -II, and PD-L1 protein expression levels of the MMRd and MMRp HGEC PDO lines measured by flow cytometry. MFI, mean fluorescent intensity. F, Colocalization of PDOs and immune cells at 14 hours of coculture period. G, Viability of the MMRd PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 and 20 hours coculture period. H, Viability of the MMRp PDO in the coculture measured by colocalization coefficient between organoid and caspase-3 signals at 12 and 20 hours coculture period. Cas3, caspase-3. Ordinary one-way ANOVA (C, G, and H) and t test (F) were used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).